These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 27383056)
1. Stiffness of the microenvironment upregulates ERBB2 expression in 3D cultures of MCF10A within the range of mammographic density. Cheng Q; Bilgin CC; Fontenay G; Chang H; Henderson M; Han J; Parvin B Sci Rep; 2016 Jul; 6():28987. PubMed ID: 27383056 [TBL] [Abstract][Full Text] [Related]
2. YY1 is a cis-regulator in the organoid models of high mammographic density. Cheng Q; Khoshdeli M; Ferguson BS; Jabbari K; Zang C; Parvin B Bioinformatics; 2020 Mar; 36(6):1663-1667. PubMed ID: 31688895 [TBL] [Abstract][Full Text] [Related]
3. Organoid model of mammographic density displays a higher frequency of aberrant colony formations with radiation exposure. Cheng Q; Parvin B Bioinformatics; 2020 Apr; 36(7):1989-1993. PubMed ID: 31778145 [TBL] [Abstract][Full Text] [Related]
4. Erratum: Stiffness of the microenvironment upregulates ERBB2 expression in 3D cultures of MCF10A within the range of mammographic density. Cheng Q; Bilgin CC; Fontenay G; Chang H; Henderson M; Han J; Parvin B Sci Rep; 2016 Aug; 6():31680. PubMed ID: 27555341 [No Abstract] [Full Text] [Related]
5. ErbB2-enhanced invasiveness of H-Ras MCF10A breast cells requires MMP-13 and uPA upregulation via p38 MAPK signaling. Yong HY; Kim IY; Kim JS; Moon A Int J Oncol; 2010 Feb; 36(2):501-7. PubMed ID: 20043086 [TBL] [Abstract][Full Text] [Related]
6. Molecular predictors of 3D morphogenesis by breast cancer cell lines in 3D culture. Han J; Chang H; Giricz O; Lee GY; Baehner FL; Gray JW; Bissell MJ; Kenny PA; Parvin B PLoS Comput Biol; 2010 Feb; 6(2):e1000684. PubMed ID: 20195492 [TBL] [Abstract][Full Text] [Related]
7. Gene expression profiling identifies sST2 as an effector of ErbB2-driven breast carcinoma cell motility, associated with metastasis. Gillibert-Duplantier J; Duthey B; Sisirak V; Salaün D; Gargi T; Trédan O; Finetti P; Bertucci F; Birnbaum D; Bendriss-Vermare N; Badache A Oncogene; 2012 Jul; 31(30):3516-24. PubMed ID: 22105364 [TBL] [Abstract][Full Text] [Related]
8. Copine-III interacts with ErbB2 and promotes tumor cell migration. Heinrich C; Keller C; Boulay A; Vecchi M; Bianchi M; Sack R; Lienhard S; Duss S; Hofsteenge J; Hynes NE Oncogene; 2010 Mar; 29(11):1598-610. PubMed ID: 20010870 [TBL] [Abstract][Full Text] [Related]
9. Granulocyte-colony stimulating factor upregulates ErbB2 expression on breast cancer cell lines and converts primary resistance to trastuzumab. Cavalloni G; Sarotto I; Pignochino Y; Gammaitoni L; Migliardi G; Sgro L; Piacibello W; Risio M; Aglietta M; Leone F Anticancer Drugs; 2008 Aug; 19(7):689-96. PubMed ID: 18594210 [TBL] [Abstract][Full Text] [Related]
10. ERBB2 overexpression triggers transient high mechanoactivity of breast tumor cells. Martin M; Müller K; Cadenas C; Hermes M; Zink M; Hengstler JG; Käs JA Cytoskeleton (Hoboken); 2012 May; 69(5):267-77. PubMed ID: 22407943 [TBL] [Abstract][Full Text] [Related]
11. Upregulation of lactate dehydrogenase A by ErbB2 through heat shock factor 1 promotes breast cancer cell glycolysis and growth. Zhao YH; Zhou M; Liu H; Ding Y; Khong HT; Yu D; Fodstad O; Tan M Oncogene; 2009 Oct; 28(42):3689-701. PubMed ID: 19668225 [TBL] [Abstract][Full Text] [Related]
12. The ErbB2ΔEx16 splice variant is a major oncogenic driver in breast cancer that promotes a pro-metastatic tumor microenvironment. Turpin J; Ling C; Crosby EJ; Hartman ZC; Simond AM; Chodosh LA; Rennhack JP; Andrechek ER; Ozcelik J; Hallett M; Mills GB; Cardiff RD; Gray JW; Griffith OL; Muller WJ Oncogene; 2016 Nov; 35(47):6053-6064. PubMed ID: 27157621 [TBL] [Abstract][Full Text] [Related]
13. Cancer cell stiffness: integrated roles of three-dimensional matrix stiffness and transforming potential. Baker EL; Lu J; Yu D; Bonnecaze RT; Zaman MH Biophys J; 2010 Oct; 99(7):2048-57. PubMed ID: 20923638 [TBL] [Abstract][Full Text] [Related]
14. Distal ERBB2 promoter fragment displays specific transcriptional and nuclear binding activities in ERBB2 overexpressing breast cancer cells. Delacroix L; Begon D; Chatel G; Jackers P; Winkler R DNA Cell Biol; 2005 Sep; 24(9):582-94. PubMed ID: 16153159 [TBL] [Abstract][Full Text] [Related]
15. Hypoxia/HIF1α induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2. Karakashev SV; Reginato MJ Oncotarget; 2015 Feb; 6(4):1967-80. PubMed ID: 25596742 [TBL] [Abstract][Full Text] [Related]
16. Effect of Actin Organization on the Stiffness of Living Breast Cancer Cells Revealed by Peak-Force Modulation Atomic Force Microscopy. Calzado-Martín A; Encinar M; Tamayo J; Calleja M; San Paulo A ACS Nano; 2016 Mar; 10(3):3365-74. PubMed ID: 26901115 [TBL] [Abstract][Full Text] [Related]
17. AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice. Grabinski N; Möllmann K; Milde-Langosch K; Müller V; Schumacher U; Brandt B; Pantel K; Jücker M Cell Signal; 2014 May; 26(5):1021-9. PubMed ID: 24463007 [TBL] [Abstract][Full Text] [Related]
18. Rapamycin together with herceptin significantly increased anti-tumor efficacy compared to either alone in ErbB2 over expressing breast cancer cells. Wang LH; Chan JL; Li W Int J Cancer; 2007 Jul; 121(1):157-64. PubMed ID: 17304506 [TBL] [Abstract][Full Text] [Related]
19. 3D culture of Her2+ breast cancer cells promotes AKT to MAPK switching and a loss of therapeutic response. Gangadhara S; Smith C; Barrett-Lee P; Hiscox S BMC Cancer; 2016 Jun; 16():345. PubMed ID: 27251376 [TBL] [Abstract][Full Text] [Related]
20. Loss of Nrdp1 enhances ErbB2/ErbB3-dependent breast tumor cell growth. Yen L; Cao Z; Wu X; Ingalla ER; Baron C; Young LJ; Gregg JP; Cardiff RD; Borowsky AD; Sweeney C; Carraway KL Cancer Res; 2006 Dec; 66(23):11279-86. PubMed ID: 17145873 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]